Autolus Therapeutics’ (AUTL) “Outperform” Rating Reiterated at William Blair

William Blair restated their outperform rating on shares of Autolus Therapeutics (NASDAQ:AUTL) in a research report sent to investors on Wednesday morning,RTT News reports.

Other equities analysts have also recently issued research reports about the stock. Wall Street Zen raised shares of Autolus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. Wells Fargo & Company dropped their target price on shares of Autolus Therapeutics from $6.00 to $5.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 13th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $10.00 price target on shares of Autolus Therapeutics in a report on Monday, July 21st. Six equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $9.12.

Autolus Therapeutics Stock Up 4.0%

NASDAQ AUTL opened at $1.56 on Wednesday. The company has a market capitalization of $415.18 million, a price-to-earnings ratio of -1.86 and a beta of 1.87. Autolus Therapeutics has a twelve month low of $1.11 and a twelve month high of $5.00. The stock has a fifty day simple moving average of $1.84 and a 200 day simple moving average of $1.79.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.06. The business had revenue of $13.50 million for the quarter, compared to analyst estimates of $12.92 million. Research analysts expect that Autolus Therapeutics will post -0.94 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC purchased a new position in Autolus Therapeutics in the fourth quarter worth $26,000. Marex Group plc bought a new stake in Autolus Therapeutics in the second quarter worth $28,000. R Squared Ltd bought a new stake in Autolus Therapeutics in the second quarter worth $50,000. Delaney Dennis R bought a new stake in Autolus Therapeutics in the second quarter worth $55,000. Finally, Forefront Wealth Management Inc. bought a new stake in Autolus Therapeutics in the second quarter worth $61,000. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.